ReviewFrontiers in immunology2021
PSGL-1 Immune Checkpoint Inhibition for CD4
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Tumor-educated-platelets interact with breast cancer-stem-cells via P-selectin-PSGL1 and ensure stemness and metastasis through WNT-β-catenin-VEGF-VEGFR2 intra-cellular signaling: therapeutic modulation by aspirin.Breast cancer research : BCR · 2025Article
- P-Selectin Glycoprotein Ligand (PSGL)-1 Expression on CD4Pathogens (Basel, Switzerland) · 2025Observational
- Adhesion to aggression: unravelling sLeClinical & experimental metastasis · 2025Review
- Article
- Comprehensive analysis of SELPLG as a potential immunotherapy target and prognostic biomarker in oncology.Discover oncology · 2025Article
- PTEN-mediated resistance in cancer: From foundation to future therapies.Toxicology reports · 2025Review
- Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure.Cell reports. Medicine · 2025Article
- Emerging IO checkpoints in gastrointestinal oncology.Frontiers in immunology · 2025Review
- Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.The breast journal · 2025Review
- Flow Cytometric Profiling of Peripheral Immune Checkpoints Predicts Prognosis and Reveals PD-1/Treg/IL-10 Crosstalk in B-Cell Lymphoma.ImmunoTargets and therapy · 2025Article
- P-selectin glycoprotein ligand-1 and cardiovascular diseases: from a general perspective to an HIV infection context.Frontiers in cardiovascular medicine · 2025Article
- Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue.Oncoimmunology · 2024Article
- An Inflammation-Related lncRNA Signature for Prognostic Prediction in Colorectal Cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth.Cancers · 2024Article
- The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response.Nature communications · 2024Article
- Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity.PLoS pathogens · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkpoints have shown promise in promoting anti-tumor immunity. PSGL-1, primarily known for its role in cellular migration, has also been shown to function as a negative regulator of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.